Related Experiment Video
Updated: Jun 17, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Commentary on pharmacotherapy of regional melanoma therapy
Importance To The Field:
Regional therapy continues to be the workhorse for the treatment of regional metastases and unresectable recurrences of melanoma limited to a limb. These approaches also offer an excellent opportunity for the study of disease biology and new drug delivery, pharmacokinetics and pharamacotherapeutics. AREAS COVERED IN THIS EDITORIAL: Utility of regional therapy as an area of study, benefits of both isolated limb infusion (ILI) and hyperthermic isolated limb perfusion (HILP) are discussed. The limitations of both approaches to regional therapy are also referenced.
What The Reader Will Gain:
This editorial serves as a companion to the peer-reviewed paper which comprehensively reviews the subject of regional therapy by Tyler et al. It offers a brief commentary on the utility of regional therapies (ILI and HILP) for extremity in-transit melanoma and their role in investigating new therapeutic modalities.
Take Home Message:
Regional therapy is an excellent therapeutic modality for disease limited to a limb and furthermore serves as an excellent model for scientific investigation, both clinical and translational.
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistant Cancers

